Overview

Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Status:
Completed

Trial end date:
2020-08-19

Target enrollment:

Participant gender:

Summary

This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.

Phase:

Phase 4

Details

Lead Sponsor:

Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company

Treatments:

Clopidogrel
Prasugrel Hydrochloride